Keryx Biopharma - KERX
- Creatore Discussione acqua+
- Data di Inizio
magolibero
..se la sà gira..
allargare il gioco con i WR ..per guadagnarne poche e sicure con RB ?
..anche se le giocate dei TE son quelle che mi piacevan di più da vedere
DickSIM
Prima o poi....ci becco!
AEterna Zentaris Inc. Partner Keryx Biopharmaceuticals Reports Positive Phase 2 Data For Perifosine (KRX-0401) In Colon And Kidney Cancer
8:35am EDT
AEterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals presented positive Phase 2 data on the clinical activity of perifosine (KRX-0401), an Akt-inhibitor compound for cancer, as a treatment for advanced metastatic colon cancer and advanced renal cell carcinoma. The poster no 4081 entitled, "Randomized Phase 2 study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer", showed that perifosine combined with capecitabine, more than doubled time to progression versus capecitabine plus placebo with a statistically significant p-value (0.0006). In addition, perifosine plus capecitabine more than doubled the Overall Response Rate and almost doubled the Clinical Benefit Rate versus capecitabine plus placebo. The poster no5034 entitled, "Phase 2 study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor", demonstrated impressive single agent efficacy of perifosine in patients who progressed after failing treatment either with a VEGF receptor inhibitor or after treatment with both a VEGF receptor inhibitor and an mTOR inhibitor.
8:35am EDT
AEterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals presented positive Phase 2 data on the clinical activity of perifosine (KRX-0401), an Akt-inhibitor compound for cancer, as a treatment for advanced metastatic colon cancer and advanced renal cell carcinoma. The poster no 4081 entitled, "Randomized Phase 2 study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer", showed that perifosine combined with capecitabine, more than doubled time to progression versus capecitabine plus placebo with a statistically significant p-value (0.0006). In addition, perifosine plus capecitabine more than doubled the Overall Response Rate and almost doubled the Clinical Benefit Rate versus capecitabine plus placebo. The poster no5034 entitled, "Phase 2 study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor", demonstrated impressive single agent efficacy of perifosine in patients who progressed after failing treatment either with a VEGF receptor inhibitor or after treatment with both a VEGF receptor inhibitor and an mTOR inhibitor.
DickSIM
Prima o poi....ci becco!
coxy
coxy
si perde terreno........se nn intervengono i panzer
la vedo male........
al momento si lavora di panza, panzer a digestione avvenuta.
DickSIM
Prima o poi....ci becco!
siamo al 30% del cs scambiato.......... con pazienza nei prox giorni si riprenderà! 
acqua+
ONDA NITRICA
ci puoi scommettere
peccato che oggi, causa volo in aereo, non abbia potuto seguire
vabbuò ,,,, tanto per il TP c'è tempo
DickSIM
Prima o poi....ci becco!
ci puoi scommettere
peccato che oggi, causa volo in aereo, non abbia potuto seguire
vabbuò ,,,, tanto per il TP c'è tempo
ti sei perso n'a fava
hanno scambaito circa il 50% del cs 
per un misero +74% 
sai com'è, ero abituato ai vandalismi...........
aspettiamo il TP